Immunocytochemical screening for papillomavirus infection in women: general characteristics and justification of the feasibility

Authors

DOI:

https://doi.org/10.18370/2309-4117.2025.76.26-32

Keywords:

papillomavirus infection, human papillomavirus, immunocytochemical screening, polymerase chain reaction, PAP test, colposcopy

Abstract

Background. Human papillomavirus (HPV) is the leading cause of cervical cancer in women. Early diagnosis of a viral lesion of the multilayer cervical squamous epithelium is extremely important for timely treatment and prevention of cancer. To diagnose papillomavirus infection and cervical lesions according to modern European and American protocols, the determination of HPV by polymerase chain reaction (PCR) and the traditional PAP test are used. An alternative method of diagnosing papillomavirus infection can be immunocytochemical (ICH) screening.
Objective of the study: to justify the feasibility of ICH screening as an alternative method for diagnosing viral lesion of the cervical epithelium.
Materials and methods. In the study cytological material from 60 patients aged 23–60 years was examined. All cases were divided into two groups: Group 1 – 30 cases from patients with HPV which was detected by PCR, Group 2 – 30 cases from patients without HPV according to PCR. All patients underwent colposcopy with taking of cytological material, ICH examination of cytological material with a BSB-66 clone of anti-HPV antibodies followed by light microscopy of the samples, PCR testing for HPV and, if necessary, pathohistological examination.
Results. The statistically significant difference between the results of ICH and PCR testing was detected: 100% of negative PCR results coincided with negative IHC results. Regarding positive cases, a coincidence was recorded in 73.33% of cases.
Conclusions. The study has shown that the ICH method of detecting HPV makes it possible to exclude the category of women who not only have persistence of the HPV, but also have its incorporation into the cells of the cervical epithelium, which may be accompanied by certain changes with the risk of developing of intraepithelial neoplasia. A greater coincidence of positive ICH reaction to HPV with abnormal colposcopy data and confirmation of the intraepithelial changes by pathohistological studies indicates the informatively of the method as a predictor of dysplastic cervical changes.

Author Biographies

I.I. Daineko, Municipal Non-Profit Enterprise «Consultative and Diagnostic Center of the Dniprovsky District of Kiev», Kyiv

obstetrician-gynecologist, Women’s consultation branch No. 2,

N.V. Kosey, SI “All-Ukrainian Center of Motherhood and Childhood of the NAMS of Ukraine”; SSI “Center for Innovative Medical Technologies of the NAS of Ukraine», Kyiv

MD, professor, chief researcher, Endocrine Gynecology Department;
head of the Department of Reproductive Health

H.V. Vetokh, SSI “Center for Innovative Medical Technologies of the NAS of Ukraine», Kyiv

PhD, researcher, Department of Reproductive Health

N.F. Zakharenko, SI “All-Ukrainian Center of Motherhood and Childhood of the NAMS of Ukraine”, Kyiv

MD, professor, leading research fellow, Endocrine Gynecology Department

S.G. Gychka, O.O. Bogomolets National Medical University, Kyiv

MD, professor, head of the Department of Pathological Anatomy

References

  1. Tesfaye E, Kumbi B, Mandefro B, et al. Prevalence of human papillomavirus infection and associated factors among women attending cervical cancer screening in setting of Addis Ababa, Ethiopia. Sci Rep. 2024 Feb 19;14(1):4053 DOI: 10.1038/s41598-024-54754-x
  2. Dziublyk IV, Kovaliuk OV. Papillomavirus infection: view the problem from the perspective of doctor-virologist. Ukrainian chemotherapeutic journal. 2012. 1-2(25):25–28.
  3. Ashaka OS, Omoare AA, James AB, et al. Prevalence and Risk Factors of Genital Human Papillomavirus Infections among Women in Lagos, Nigeria. Trop Med Infect Dis. 2022 Nov 18;7(11):386. DOI:10.3390/tropicalmed7110386
  4. Koutsky L. Epidemiology of Genital Human Papillomavirus Infection. Am J Med. 1997 May 5;102(5A):3-8. DOI:10.1016/s0002-9343(97)00177-0
  5. HPV and Cancer. Comprehensive Cancer Information. [Internet]. NCI. 2025 Jan 31. Available from: https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-and-cancer
  6. Vats A, Trejo-Cerro O, Thomas M, Banks L. Human papillomavirus E6 and E7: What remains? Tumour Virus Res. 2021 Jun;11:200213. DOI: 10.1016/j.tvr.2021.200213.
  7. Mittal S, Banks L. Molecular mechanisms underlying human papillomavirus E6 and E7 oncoprotein-induced cell transformation. Mutat Res Rev Mutat Res. 2017 Apr-Jun;772:23-35. DOI: 10.1016/j.mrrev.2016.08.001.
  8. Egawa N, Doorbar J. The low-risk papillomaviruses. Virus Res. 2017;231:119–27. DOI: 10.1016/j. virusres.2016.12.017.
  9. Jensen JE, Becker GL, Jackson JB, Rysavy MB. Human Papillomavirus and Associated Cancers. A Review. Viruses 2024; 16:680. DOI: 10.3390/v16050680
  10. Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8:e191–e203. DOI:10.1016/S2214-109X(19)30482-6
  11. Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020 Jul;40(5):602-608. DOI: 10.1080/01443615.2019.1634030.
  12. Ramakrishnan S, Partricia S, Mathan G. Overview of high-risk HPV’s 16 and 18 infected cervical cancer: pathogenesis to prevention. Biomed Pharmacother. 2015 Mar;70:103–10. DOI: 10.1016/j. biopha.2014.12.041.
  13. Ahmed HG, Bensumaidea SH, Alshammari FD, et al. Prevalence of Human Papillomavirus subtypes 16 and 18 among Yemeni Patients with Cervical Cancer. Asian Pac J Cancer Prev. 2017 Jun 25;18(6):1543–1548. DOI: 10.22034/APJCP.2017.18.6.1543.
  14. Pešut E, Đukić A, Lulić L, et al. Human Papillomaviruses-Associated Cancers: An Update of Current Knowledge. Viruses. 2021 Nov 6;13(11):2234. DOI: 10.3390/v13112234
  15. HPV Antibody (BSB-66) – Bio SB. [Internet]. Bio SB. Available from: https://www.biosb.com/biosb-products/hpv-antibody-mmab-bsb-66/
  16. The American Cancer Society Guidelines for the Prevention and Early Detection of Cervical Cancer. Information and Resources about Cancer: Breast, Colon, Lung, Prostate, Skin [Internet]. American Cancer Society. Available from: https://www.cancer.org/cancer/types/cervical-cancer/detection-diagnosis-staging/cervical-cancer-screening-guidelines.html
  17. New ACS Cervical Cancer Screening Guideline. [Internet]. Comprehensive Cancer Information - NCI. 2020. Sep 18. Available from: https://www.cancer. gov/news-events/cancer-currents-blog/2020/cervical-cancer-screening-hpv-test-guideline
  18. Koliopoulos G, Nyaga VN, Santesso N, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 2017 Aug 10;8(8):CD008587. DOI: 10.1002/14651858.CD008587.pub2.
  19. Updated Cervical Cancer Screening Guidelines. [Internet]. ACOG. 2024 Apr. Available from: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/04/updated-cervical-cancer-screening-guidelines
  20. Li YC, Zhao YQ, Li TY, et al. The Performance of Immunocytochemistry Staining as Triaging Tests for High-Risk HPV-Positive Women: A 24-Month Prospective Study. J Oncol. 2020 May 26:2020:6878761. DOI: 10.1155/2020/6878761
  21. Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interimclinical guidance. Gynecol Oncol. 2015;136(2):178–182. DOI: 10.1016/j.ygyno.2014.12.022
  22. Schiffman M, de Sanjose S. False positive cervical HPV screening test results. Papillomavirus Res. 2019 Jun:7:184–187.. DOI:10.1016/j. pvr.2019.04.012
  23. Shidham VB. Role of immunocytochemistry in cervical cancer screening. Cytojournal. 2022 Jun 14:19:42. DOI: 10.25259/cmas_03_17_2022
  24. Fei M, Yu Y, Hu X, et al. The Value of Immunocytochemical Staining for the HPV E7 Protein in the Diagnosis of Cervical Lesions. Int J Gen Med. 2023 Mar 24:16:1081–1089. DOI: 10.2147/IJGM.S402759
  25. Villa LL, Denny L. CHAPTER 7 Methods for detection of HPV infection and its clinical utility. Int J Gynecol Obstet. 2006 Nov:94 Suppl 1:S71–S80. DOI: 10.1016/s0020-7292(07)60013-7

Downloads

Published

2025-03-31

How to Cite

Daineko, I., Kosey, N., Vetokh, H., Zakharenko, N., & Gychka, S. (2025). Immunocytochemical screening for papillomavirus infection in women: general characteristics and justification of the feasibility. REPRODUCTIVE ENDOCRINOLOGY, (76), 26–32. https://doi.org/10.18370/2309-4117.2025.76.26-32

Issue

No. 76 (2025)

Section

Health care

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.